+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Not Verified

Clinical trials to advance therapies for cardiovascular disease in type 1 diabetes

Breakthrough T1D

Summary

• The goal of this funding opportunity is to advance therapies to improve cardiovascular outcomes in people with established type 1 diabetes (T1D).

• This funding opportunity will prioritize clinical trials evaluating promising therapies, whether repositioned, repurposed, in development, or already approved, for cardiovascular disease (CVD) in people with T1D.

• This initiative will award grants for clinical studies to academic investigators and industry partners of up to $3,000,000.00 over 3 years.

Funding Opportunity Description

Breakthrough T1D is committed to the development of therapies to improve clinical outcomes in people with type 1 diabetes (T1D). Cardiovascular disease (CVD) is the primary cause of morbidity and mortality in people with T1D. There is currently a lack of targeted therapies for CVD approved for use by people with T1D, in part because people with T1D are seldom included in drug trials for these diabetic complications. To fill this gap, Breakthrough T1D invites applications for clinical trials to advance therapies to improve CVD outcomes in T1D.

Funding Mechanisms In response to this announcement, applications may request up to a total of $3,000,000 USD for up to three years.

• The level of funding will vary depending on the scope and overall objectives of the proposal. Breakthrough T1D may consider applications with increased scope (time, budget) where there is a strong justification, and applicants interested in such should discuss with the Breakthrough T1D scientific contact below.

• Note that the above budget figure is a maximum, and Breakthrough T1D will also consider projects with substantially smaller budgets. In all cases, the level of requested funding should be commensurate with the studies proposed and non-Breakthrough T1D resources (funds, personnel, other) available to successfully complete the project. Appropriateness of budget in relation to scope will be considered as part of the review criteria.

AI Based Application Success Predictor

1️⃣ Explicit Relevance to Type 1 Diabetes (not Type 2)

Breakthrough T1D reviewers heavily emphasize:

Autoimmune destruction of beta cells

T1D-specific immune pathways

Beta-cell replacement, regeneration, protection

T1D metabolic mechanisms and glycemic outcomes

Life-stage specific issues (children, adolescents, adults with long-standing T1D)

👉 Applications that apply generic diabetes science without a T1D-specific mechanism score poorly.

2️⃣ Strong Translational Potential — Pathway to Patient Benefit

Breakthrough T1D is extremely translational:

Funded studies usually have a clear connection to:

Clinical trials

Prototype or preclinical therapeutic development

Biomarker qualification

Safety/efficacy through human tissue or in vivo models

Real-world digital health or AID system improvements

Predictor: The proposal shows how the work could advance toward clinical benefit within 3–7 years.

3️⃣ Alignment With Current Strategic Priorities

The foundation frequently updates its priority areas.

Consistently strong areas include:

Immune therapies (antigen-specific, targeted immunomodulation)

Stem-cell–derived beta cells & islet replacement therapies

Encapsulation technologies

Biomarkers of progression, prediction, or therapeutic response

Adjunct therapies for glucose stability

Automated insulin delivery algorithms & devices

Hypoglycemia unawareness & complications

Pediatric/adolescent outcomes

Predictor: Proposals that directly address these priority programs are much more competitive.

4️⃣ High-Risk, High-Reward Innovation (Backed by Rationale)

Breakthrough T1D actively embraces bold, transformative ideas if supported by a reasonable scientific foundation.

Strong proposals exhibit:

Novel immune targets

New biomaterials or encapsulation strategies

First-in-class therapeutics

Cutting-edge sensors or algorithmic innovations

Engineering/bioinformatics approaches to T1D biology

👉 Innovation must be balanced with feasibility — not speculation.

5️⃣ Robust Preliminary Data (especially for translational or therapeutic proposals)

Competitive projects usually include:

Pilot in vitro or in vivo data

Feasibility results

Early proof-of-concept

Strong rationale from high-quality earlier studies

Early-career grants may allow less preliminary data but still require strong justification.

Predictor: Evidence that the approach is ready to advance → reduces perceived risk.

6️⃣ High-Quality Research Environment & Team

Breakthrough T1D prefers teams with:

Expertise in T1D immunology, beta-cell biology, or device engineering

Access to specialized facilities (immunology, stem cell labs, imaging, device design)

Clinical infrastructure if human samples or trials are involved

Multidisciplinary collaboration (clinicians + immunologists + bioengineers + data scientists)

Predictor: A strong, multidisciplinary team with relevant track record.

7️⃣ Clear Milestones & Go/No-Go Criteria

Many Breakthrough T1D programs use milestone-based funding.

Strong proposals outline:

Specific deliverables tied to project phases

Quantifiable success metrics

Realistic timelines

Defined risk mitigation strategies

Predictor: Clear milestones = confidence in project management & feasibility.

8️⃣ Patient and Community Impact (Including Psychosocial Research)

Breakthrough T1D increasingly values:

Quality of life

Burden of daily management

Mental health in T1D

Health equity and underserved populations

Adoption and usability of diabetes technology

Predictor: Proposals with direct benefit to people living with T1D, beyond biological mechanisms, have growing priority.

🚫 Common Pitfalls That Weaken Applications

Pitfall	Why It Hurts
Too generic — applies to T2D, not T1D	Lacks mission alignment
Overly ambitious multi-aim project	Feasibility concerns
Weak or no preliminary data	Too speculative
Poor translational pathway	Reviewers can’t see clinical relevance
Unclear milestones or deliverables	Risk of project drift
Lack of expertise on team	Execution risk
No patient impact or equity considerations	Misses strategic shifts

🎯 Breakthrough T1D Proposal Success Checklist

✔ T1D-specific mechanisms, targets, or patient issues
✔ Strong translational trajectory (bench → clinic)
✔ Fits one or more current strategic priority areas
✔ Robust preliminary data or compelling rationale
✔ Feasible, milestone-driven experimental plan
✔ Multidisciplinary and experienced team
✔ Clear patient benefit or equity dimension
✔ Lean, justified budget
✔ Clear path to future funding or clinical trials

Specialties

Cardiovascular Diseases

Diabetes

Clinical Trials

Eligibility Requirements

Applications may be submitted by domestic and foreign non-profit organizations, public and private, such as universities, colleges, hospitals, laboratories, units of state and local governments, and eligible agencies of the federal government. Applicants must hold an M.D., D.O., D.M.D., D.V.M., Ph.D., or equivalent and have a faculty position or equivalent at a college, university, medical school, or other research facility.

• There are no citizenship requirements for this program. To assure continued excellence and diversity among applicants and awardees, Breakthrough T1D welcomes applications from all qualified individuals and encourages applications from persons with disabilities, women, and members of minority groups underrepresented in the sciences.

Sponsor Details

Sponsor Institute/Organizations: Breakthrough T1D

Sponsor Type: Corporate/Non-Profit

Address: 200 Vesey Street, 28th Floor New York, NY 10281

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity